West Pharmaceutical Services Inc. (NYSE:WST) declared a quarterly dividend on Thursday, May 9th, Wall Street Journal reports. Investors of record on Wednesday, July 24th will be paid a dividend of 0.15 per share by the medical instruments supplier on Wednesday, August 7th. This represents a $0.60 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date is Tuesday, July 23rd.

West Pharmaceutical Services has raised its dividend by an average of 8.2% annually over the last three years and has increased its dividend every year for the last 26 years. West Pharmaceutical Services has a dividend payout ratio of 21.3% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect West Pharmaceutical Services to earn $3.28 per share next year, which means the company should continue to be able to cover its $0.60 annual dividend with an expected future payout ratio of 18.3%.

Shares of NYSE:WST opened at $121.41 on Monday. The stock has a market cap of $8.92 billion, a PE ratio of 43.21, a PEG ratio of 3.68 and a beta of 1.30. The stock has a fifty day simple moving average of $121.60. West Pharmaceutical Services has a 52 week low of $91.75 and a 52 week high of $127.06. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.13 and a current ratio of 2.88.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, April 25th. The medical instruments supplier reported $0.74 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.08. The company had revenue of $443.50 million for the quarter, compared to analysts’ expectations of $431.00 million. West Pharmaceutical Services had a net margin of 12.53% and a return on equity of 16.38%. The firm’s revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.62 EPS. On average, equities research analysts predict that West Pharmaceutical Services will post 2.88 EPS for the current fiscal year.

A number of equities analysts recently commented on WST shares. Zacks Investment Research cut shares of Inflarx from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Jefferies Financial Group lifted their target price on shares of EXACT Sciences from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Finally, William Blair restated an “outperform” rating on shares of bluebird bio in a research report on Tuesday, April 23rd.

In other West Pharmaceutical Services news, VP Daniel Malone sold 4,458 shares of the business’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $123.03, for a total value of $548,467.74. Following the transaction, the vice president now owns 33,478 shares in the company, valued at $4,118,798.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.70% of the stock is currently owned by insiders.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Further Reading: Dividend Aristocrat Index

Dividend History for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.